HomeInsightsStock Comparison

Cipla Ltd vs Zydus Lifesciences Ltd Stock Comparison

Cipla Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jul 04, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1513 as of 04 Jul 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Cipla Ltd News Hub

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

Zydus Lifesciences Ltd News Hub

News

Zydus Life Matoda facility receives two observations from USFDA after inspection

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspect...

Read more

19 Jun 2025 09:50

News

Zydus Lifesciences appoints Managing Director

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Direct...

Read more

16 Jun 2025 14:16

News

Zydus Life subsidiary ZHL appoints Swati Dalal as MD

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dal...

Read more

16 Jun 2025 14:42

News

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the r...

Read more

12 Jun 2025 09:55

News

Zydus' Ankleshwar API unit clears USFDA inspection

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the ...

Read more

12 Jun 2025 10:41

News

Zydus Lifesciences Ltd spurts 0.24%, up for fifth straight session

Zydus Lifesciences Ltd is up for a fifth straight session today. The stock is quoting at R...

Read more

10 Jun 2025 13:00

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Cipla Ltd or Zydus Lifesciences Ltd?

Market cap of Cipla Ltd is 122,246 Cr while Market cap of Zydus Lifesciences Ltd is 100,724 Cr

What are the key factors driving the stock performance of Cipla Ltd and Zydus Lifesciences Ltd?

The stock performance of Cipla Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Zydus Lifesciences Ltd?

As of July 4, 2025, the Cipla Ltd stock price is INR ₹1513.5. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹1001.0.

How do dividend payouts of Cipla Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Cipla Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions